2020
Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
Cawley J, Wright Z, Meleo K, Post G, Clifford C, Vickery K, Vail D, Bergman P, Thamm D. Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs. Journal Of Veterinary Internal Medicine 2020, 34: 882-889. PMID: 32064697, PMCID: PMC7096650, DOI: 10.1111/jvim.15723.Peer-Reviewed Original ResearchConceptsMedian progression-free survival timeOverall response rateComplete responseMulticentric lymphomaAdverse eventsL-asparaginaseProspective single-arm clinical trialProgression-free survival timeSingle-arm clinical trialNegative prognostic factorRelapse of lymphomaTreatment of lymphomaNovel antineoplastic agentPrognostic factorsChemotherapy protocolsClinical trialsRabacfosadineSurvival timeIU/Response rateClinical importanceLymphomaMultivariate analysisAntineoplastic agentsConcurrent use
2017
Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma
Thamm D, Vail D, Post G, Fan T, Phillips B, Axiak‐Bechtel S, Elmslie R, Klein M, Ruslander D. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma. Journal Of Veterinary Internal Medicine 2017, 31: 872-878. PMID: 28370378, PMCID: PMC5435064, DOI: 10.1111/jvim.14700.Peer-Reviewed Original ResearchConceptsProgression-free intervalMulticentric lymphomaComplete responseOverall median progression-free intervalMedian progression-free intervalMulticenter prospective clinical trialSubstantial single-agent activityAdverse effect profileAssessment of remissionMost adverse eventsProspective clinical trialsSingle-agent activityLong-term outcomesOverall response rateCanine multicentric lymphomaDermatologic AEsHematologic AEsClinicopathological evaluationAdverse eventsChemotherapy combinationsCombination chemotherapyTreatment visitsUntreated lymphomaEffect profilePulmonary fibrosis